Skip to main content
Signal8

Arcus Biosciences, Inc. (RCUS)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Arcus Biosciences, Inc. logo

Arcus Biosciences, Inc.

NYSE:RCUSHealthcare
Pre+0.22%$18.32
Close$18.28+3.34%AH$18.28+0.22%since
Mkt Cap$2.63B
Float90.58M
O/S143.99M
PM VOL231 sh
$ Vol≈$4K
RVOL0.10×
Inst Own63.4%
SI13.6%
Dilution
Arcus Biosciences, Inc. logoNYSE:RCUSPre$18.32+0.22%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202617.9518.5017.5118.281,055,364
Nov 5, 202619.2919.4217.5017.692,036,343
Nov 4, 202619.5119.6318.6019.312,078,154
Nov 3, 202618.1218.9818.0518.911,935,572
Nov 2, 202618.2318.4917.7617.851,380,503
Oct 30, 202618.3418.8917.8118.191,935,910
Oct 29, 202618.6219.0218.1118.611,665,762
Oct 28, 202617.8518.5017.7618.392,018,621
Oct 27, 202617.6218.3317.5318.142,231,836
Oct 26, 202618.3718.6117.6317.762,699,612
Oct 23, 202619.0219.0918.4318.545,925,217
Oct 22, 202617.4319.6217.4319.368,370,963
Oct 21, 202624.4724.4718.9819.104,654,347
Oct 20, 202621.2624.7020.8123.756,242,268
Oct 19, 202622.4422.9421.3722.143,516,697
Oct 16, 202622.7922.9521.6022.121,425,533
Oct 15, 202622.5323.2822.5322.821,210,182
Oct 14, 202622.8223.4722.3622.531,211,972
Oct 13, 202623.8724.0022.4622.511,393,549
Oct 12, 202624.4224.7324.1224.341,337,989
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
15
HOLD
3
SELL
0
TOTAL18
Insider Trades
InsiderTypeShares
Azoy Alexander profile photoAzoy AlexanderOption Exercise2.8K
Azoy Alexander profile photoAzoy AlexanderSale2.8K
Azoy Alexander profile photoAzoy AlexanderOption Exercise2.8K
Jaen Juan C. profile photoJaen Juan C.Sale268
Jaen Juan C. profile photoJaen Juan C.Sale19.8K
Jaen Juan C. profile photoJaen Juan C.Sale48.5K
Shareholders
63.4%
Institutional
(237)
1.0%
Insiderⓘ
(14)
24.5%
5%+ Owners
(2)
11.1%
Unattributed (incl. retail)ⓘ
Institutional63.4%
Insider1.0%
5%+ Beneficial24.5%
Unattributed (incl. retail)11.1%
Sources: 13F, Form 4, 13D/13GO/S: 144.0M · as of 29 Oct 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer.

In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer.

It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Key Metrics
Market Cap$2.63B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership63.43%

based on 143.99M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNYSE
CountryUSUS
IPO DateMar 15, 2018
Shares Outstanding143.99M
Authorized Shares
Float90.58M
52-Week Range
$17.43$31.73
$18.28(6th percentile)
Volume
Average Daily Volume2.72M
1.06M today vs 2.72M avg(-61%)

30d Avg

2.72M

60d Avg

2.20M

90d Avg

1.87M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...